Literature DB >> 22684725

Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011.

Anne Hackenberg1, Gökhan Arman-Kalcek, Jens Hiller, Gülsah Gabriel.   

Abstract

Location- and age-specific prevalence of antibodies against 2009 pandemic influenza A (H1N1) virus were determined in sera of blood donors collected during winter 2010/2011 in Germany. Prevalence of antibodies at protective titres (HI ≥1:40) varied significantly between cities (24.13-83.67 %) throughout all age groups. However, high level antibodies (HI >1:80) were most prevalent among young individuals (18-29 and 30-39 years). Overall, this study demonstrates that older people (50-59 and 60-70 years) are no longer more likely to present protective antibody titres against 2009 pandemic influenza A (H1N1) virus than younger individuals. Furthermore, our data show a highly variable immunity among the German population in different major cities almost 2 years after the detection of first cases in Germany.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22684725     DOI： 10.1007/s00430-012-0251-4

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  27 in total

1.  Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.

Authors:  J Delangue; N Salez; L Ninove; A Kieffer; C Zandotti; M Seston; B Lina; A Nougairede; R Charrel; A Flahault; X de Lamballerie
Journal:  Clin Microbiol Infect       Date:  2011-06-02       Impact factor: 8.067

2.  H1N1v at a seroepidemiological glance: is the nightmare over?

Authors:  C Reinheimer; H W Doerr; I Friedrichs; M Stürmer; R Allwinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-09       Impact factor: 3.267

3.  Mortality of 2009 pandemic influenza A(H1N1) in Germany.

Authors:  H Wilking; S Buda; E von der Lippe; D Altmann; G Krause; T Eckmanns; W Haas
Journal:  Euro Surveill       Date:  2010-12-09

4.  Vaccinate for the next H2N2 pandemic now.

Authors:  Gary J Nabel; Chih-Jen Wei; Julie E Ledgerwood
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

5.  2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore.

Authors:  Mark I C Chen; Vernon J M Lee; Wei-Yen Lim; Ian G Barr; Raymond T P Lin; Gerald C H Koh; Jonathan Yap; Lin Cui; Alex R Cook; Karen Laurie; Linda W L Tan; Boon Huan Tan; Jimmy Loh; Robert Shaw; Chris Durrant; Vincent T K Chow; Anne Kelso; Kee Seng Chia; Yee Sin Leo
Journal:  JAMA       Date:  2010-04-14       Impact factor: 56.272

6.  Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 - results from thirteen consecutive cross-sectional surveys.

Authors:  Dietmar Walter; Merle M Böhmer; Matthias an der Heiden; Sabine Reiter; Gérard Krause; Ole Wichmann
Journal:  Vaccine       Date:  2011-04-02       Impact factor: 3.641

7.  Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?

Authors:  Regina Allwinn; Janina Geiler; Annemarie Berger; J Cinatl; H W Doerr
Journal:  Med Microbiol Immunol       Date:  2010-02-17       Impact factor: 3.402

8.  Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.

Authors:  Patricia R Blank; Matthias Schwenkglenks; Thomas D Szucs
Journal:  J Infect       Date:  2009-04-17       Impact factor: 6.072

9.  Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter.

Authors:  Gwendolyn L Gilbert; Michelle A Cretikos; Linda Hueston; George Doukas; Brian O'Toole; Dominic E Dwyer
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

10.  Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany.

Authors:  Rüdiger von Kries; Susanne Weiss; Gerhard Falkenhorst; Stephan Wirth; Petra Kaiser; Hans-Iko Huppertz; Tobias Tenenbaum; Horst Schroten; Andrea Streng; Johannes Liese; Sonu Shai; Tim Niehues; Hermann Girschick; Ellen Kuscher; Axel Sauerbrey; Jochen Peters; Carl Heinz Wirsing von König; Simon Rückinger; Walter Hampl; Detlef Michel; Thomas Mertens
Journal:  PLoS One       Date:  2011-09-07       Impact factor: 3.240
View more
  5 in total

1.  Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany.

Authors:  Andi Krumbholz; Jeannette Lange; Ralf Dürrwald; Mario Walther; Thomas H Müller; Detlef Kühnel; Peter Wutzler; Andreas Sauerbrei; Roland Zell
Journal:  Med Microbiol Immunol       Date:  2013-09-08       Impact factor: 3.402

Review 2.  Vaccination against infectious diseases: what is promising?

Authors:  Hans Wilhelm Doerr; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2014-07-27       Impact factor: 3.402

3.  Anti-Human H1N1pdm09 and swine H1N1 Virus Antibodies among Swine Workers in Guangdong Province, China.

Authors:  Jie Wu; Lina Yi; Hanzhong Ni; Lirong Zou; Hongbin Zhang; Xianqiao Zeng; Lijun Liang; Laiqing Li; Haojie Zhong; Xin Zhang; Jin-yan Lin; Changwen Ke
Journal:  Sci Rep       Date:  2015-07-24       Impact factor: 4.379

4.  Detecting a Surprisingly Low Transmission Distance in the Early Phase of the 2009 Influenza Pandemic.

Authors:  Valentina Marziano; Andrea Pugliese; Stefano Merler; Marco Ajelli
Journal:  Sci Rep       Date:  2017-09-26       Impact factor: 4.379

5.  Mutations in the H7 HA and PB1 genes of avian influenza a viruses increase viral pathogenicity and contact transmission in guinea pigs.

Authors:  Carola Dreier; Patricia Resa-Infante; Swantje Thiele; Stephanie Stanelle-Bertram; Kerstin Walendy-Gnirß; Thomas Speiseder; Annette Preuss; Zacharias Müller; Hans-Dieter Klenk; Jürgen Stech; Gülsah Gabriel
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.